Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 2,243 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

The Effects of the Food Preservative Propionic Acid in Post-prandial Metabolism

NCT01889446
View directory record Official record
Conditions
Obesity, Insulin Resistance, Diabetes
Interventions
Calcium propionate
Dietary Supplement
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 17, 2026, 6:25 PM EDT
Terminated Phase 1Phase 2 Interventional

Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-100 in Duchenne Muscular Dystrophy

NCT01847573
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
HT-100
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
6 Years to 20 Years · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalence Study of Loperamide Hydrochloride 2 mg and Simethicone 125 mg Tablet Under Fasting Conditions

NCT00778115
View directory record Official record
Conditions
Healthy
Interventions
Loperamide HCl 2 mg and simethicone 125 mg tablets
Drug
Lead sponsor
Ranbaxy Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 23, 2008 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability of Formulations of CKD-510 and to Assess the Effect of Food on the CKD-510 Tablet Formulation in Healthy Subjects

NCT05526742
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CKD-510 capsule (reference), CKD-510 tablet (test)
Drug
Lead sponsor
Chong Kun Dang Pharmaceutical
Industry
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Modernization of in vivo-in Vitro Oral Bioperformance Prediction and Assessment

NCT02806869
View directory record Official record
Conditions
Human Gastrointestinal Physiology Data
Interventions
Single dose of ibuprofen (800 mg tablet), Pulmocare, two 8.0 oz (236.6 mL) cans
Drug · Dietary Supplement
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Satiety of High-Protein Ramen Noodles

NCT05725681
View directory record Official record
Conditions
Appetitive Behavior
Interventions
High protein ramen, Standard ramen
Other
Lead sponsor
Texas Tech University
Other
Eligibility
25 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2025 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of the Timing of a Meal on the Pharmacokinetics of Entinostat

NCT02922946
View directory record Official record
Conditions
Volunteers, Healthy Volunteers, Human Volunteers, Normal Volunteers
Interventions
Entinostat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
19 Years to 55 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Oct 17, 2026, 6:25 PM EDT
Terminated Not applicable Interventional Results available

2-5 Intermittent Caloric Restriction in HIV

NCT03489109
View directory record Official record
Conditions
Human Immunodeficiency Virus, Metabolic Syndrome
Interventions
Intermittent fasting, Standard of Care
Behavioral · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Ondansetron Orally Disintegrating Tablets 8 mg to Zofran ODT® Tablets 8 mg

NCT00649363
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron Orally Disintegrating Tablets 8 mg, Zofran ODT® Tablets 8 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 17, 2026, 6:25 PM EDT
Not listed Not applicable Interventional

High Intensity Interval Gait Training in Multiple Sclerosis

NCT05529498
View directory record Official record
Conditions
Multiple Sclerosis,Gait, Exercise
Interventions
Moderate paced continuous gait training, High Intensity Interval gait training
Behavioral
Lead sponsor
City University of New York
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Meloxicam Tablets Under Fasting Conditions

NCT00618163
View directory record Official record
Conditions
Inflammation
Interventions
Meloxicam
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 6:25 PM EDT
Terminated Phase 2 Interventional

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

NCT02109016
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, NSCLC, Small Cell Lung Cancer, SCLC, Lung Cancer, Advanced Lung Cancer, Metastatic Lung Cancer, Stage IV Lung Cancer
Interventions
Lucitanib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 17, 2026, 6:25 PM EDT
Withdrawn Not applicable Interventional

The Effect of Intermittent Fasting on Body Composition in Women With Breast Cancer

NCT04691999
View directory record Official record
Conditions
Breast Cancer
Interventions
Intermittent Fasting
Behavioral
Lead sponsor
Duke University
Other
Eligibility
20 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 23, 2021 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bioavailability Study of Fixed Dose Combination (FDC) Formulations of Dapagliflozin and Metformin XR Versus Individual Component Coadministered to Healthy Subjects in a Fasted State

NCT01002807
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Dapagliflozin, Metformin XR, Glucophage
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2016 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

NCT03627936
View directory record Official record
Conditions
Healthy Participants
Interventions
Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Clarithromycin Tablets Under Fasting Conditions

NCT00601315
View directory record Official record
Conditions
Infection
Interventions
Clarithromycin
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

NCT05349864
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07284890 Treatment A, PF-07284890 Treatment B, PF-07284890 Treatment C
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Different Formulations of LY3410738 in Healthy Adult Participants

NCT06181084
View directory record Official record
Conditions
Healthy
Interventions
LY3410738, Esomeprazole
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 26, 2023 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Ondansetron Tablets 24 mg and Zofran® Tablets 24 mg

NCT00649532
View directory record Official record
Conditions
Healthy
Interventions
Ondansetron Tablets 24 mg, Zofran® Tablets 24 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

NCT02257398
View directory record Official record
Conditions
Infections, Respiratory Tract
Interventions
GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2017 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Bioavailability Study of Codeine Sulfate

NCT01010152
View directory record Official record
Conditions
Pain
Interventions
Codeine Sulfate
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional

Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors

NCT00618735
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
BIIB021
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Encinitas, California • Santa Monica, California • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Pharmacokinetics of Fostamatinib in Fed and Fasted State in Combination With Ranitidine to Assess Bioavailability

NCT01682408
View directory record Official record
Conditions
Pharmacokinetics
Interventions
Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference), Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed, Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A), Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B), Ranitidine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 28, 2012 · Synced Oct 17, 2026, 6:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

NCT01930006
View directory record Official record
Conditions
Advanced Malignancies
Interventions
MGCD265
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2015 · Synced Oct 17, 2026, 6:25 PM EDT